Avantor, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022
October 28, 2022 at 08:00 am EDT
Share
Avantor, Inc. provided earnings guidance for the fourth quarter and full year of 2022. For the fourth quarter, this reflects approximately 2% to 4% core organic revenue growth and about 4% COVID headwind, resulting in flat to low single-digit decline in organic revenue. They expect reported revenue of roughly $1.775 billion to $1.815 billion in the fourth quarter.
The company now updated full year guidance to reflect third quarter performance, $400 million of expected revenue from 2021 acquisitions. Starting with revenue, they expect full year core organic revenue growth of 6% to 6.5% and COVID headwinds of about 3.5%, resulting in organic revenue growth of approximately 2.5% to 3%. Including the inorganic contribution from M&A of 4% or roughly $270 million and FX headwinds of approximately 5% or roughly $350 million, they expect reported growth of 1.5% to 2% for 2022.
Avantor, Inc. is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies & applied materials industries. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables include chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
AVANTOR, INC. 
